TYK MEDICINES-B (02410) announced that its investigational Class 1 new drug, Aidosertinib Mesylate Tablets (TY-9591 tablets), has been included in the Priority Review品种 list by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). The proposed indication for Aidosertinib Mesylate Tablets (TY-9591 tablets) is the first-line treatment of adult patients with locally advanced or metastatic NSCLC who have EGFR exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutations, accompanied by CNS metastases.